Printer Friendly

ENZYTECH APPOINTS HAYS AS PRESIDENT AND CEO

 ENZYTECH APPOINTS HAYS AS PRESIDENT AND CEO
 CAMBRIDGE, Mass., May 7 /PRNewswire/ -- Enzytech, Inc. announced


today the appointment of Russell D. Hays as president and chief executive officer of the company. Hays joins Enzytech from Baxter Healthcare Corporation, where he served as vice president and general manager, immunotherapy.
 "Russ Hays' appointment is a major milestone for Enzytech and our program for building a major business in novel delivery systems for therapeutic proteins and peptides," said Mark Skaletsky, chairman of Enzytech. "Russ brings to Enzytech an outstanding track record at Baxter and at Stryker Corporation in planning and executing strategies for commercializing healthcare products based on advanced technology."
 Since joining Baxter Healthcare in 1985, Hays has served in a number of planning and operating management positions, including vice president of planning & business development-hospital products; vice president of marketing & business development-V. Mueller division and corporate vice president for technology assessment and planning. He was appointed to his current position in 1990 and rapidly built the company's program in immunotherapy into a significant operating business.
 Prior to Baxter Healthcare, he served as general manager of Stryker Corporation's surgical arthroscopy division. Before joining Stryker, he held a number of technical management positions at Baxter Travenol Laboratories.
 Hays holds a bachelor of science degree in physics from Elmhurst College (Illinois) and a masters degree in management from the Kellogg Graduate School of Management at Northwestern University.
 Based in Cambridge, Mass., Enzytech is a biotechnology company developing and commercializing patentable delivery systems for therapeutic proteins and peptides.
 -0- 5/7/92
 /CONTACT: Mark Skaletsky of Enzytech, 617-252-0001, or Robert Gottlieb of Feinstein Partners, 617-577-8110, for Enzytech/ CO: Enzytech, Inc. ST: Massachusetts IN: MTC SU: PER


SH -- NE002 -- 7429 05/07/92 08:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 7, 1992
Words:288
Previous Article:BEST BUY COMPANY REPORTS APRIL 1992 SALES
Next Article:HECLA REPORTS FIRST-QUARTER EARNINGS
Topics:


Related Articles
CYTOMED NAMES THOMAS R. BECK, M.D., CHAIRMAN, CHIEF EXECUTIVE OFFICER
MARK SKALETSKY NAMED PRESIDENT AND CEO OF GELTEX INC.
Executive changes. (Random Samples).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters